154 related articles for article (PubMed ID: 34775003)
1. The IVF-generated human embryonic microenvironment reverses progestin resistance in endometrial cancer cells by inducing cancer stem cell differentiation.
Sun D; Qin Z; Xu Y; Xiao Q; Xu Y; Bai M; Li W; Liu Y; Zheng W; Zhang Z
Cancer Lett; 2022 Feb; 526():311-321. PubMed ID: 34775003
[TBL] [Abstract][Full Text] [Related]
2. Metformin reverses progestin resistance in endometrial cancer cells by downregulating GloI expression.
Zhang Z; Dong L; Sui L; Yang Y; Liu X; Yu Y; Zhu Y; Feng Y
Int J Gynecol Cancer; 2011 Feb; 21(2):213-21. PubMed ID: 21270604
[TBL] [Abstract][Full Text] [Related]
3. Metformin sensitizes endometrial cancer cells to progestin by targeting TET1 to downregulate glyoxalase I expression.
Jiang Y; Chen X; Wei Y; Feng Y; Zheng W; Zhang Z
Biomed Pharmacother; 2019 May; 113():108712. PubMed ID: 30849641
[TBL] [Abstract][Full Text] [Related]
4. RNA-seq and ATAC-seq analysis of CD163
Wang L; Lv Q; Wu P; Luo S; Liu S; Chen X; Luo X
Cancer Med; 2023 Mar; 12(5):5964-5978. PubMed ID: 36373483
[TBL] [Abstract][Full Text] [Related]
5. TSLP enhances progestin response in endometrial cancer via androgen receptor signal pathway.
Lv M; Xu Y; Chen P; Li J; Qin Z; Huang B; Liu Y; Tao X; Xiang J; Wang Y; Feng Y; Zheng W; Zhang Z; Li L; Liao H
Br J Cancer; 2024 Mar; 130(4):585-596. PubMed ID: 38172534
[TBL] [Abstract][Full Text] [Related]
6. Brusatol sensitizes endometrial hyperplasia and cancer to progestin by suppressing NRF2-TET1-AKR1C1-mediated progestin metabolism.
Hu M; Sun D; Yu J; Fu Y; Qin Z; Huang B; Zhang Q; Chen X; Wei Y; Zhu H; Wang Y; Feng Y; Zheng W; Liao H; Li J; Wu S; Zhang Z
Lab Invest; 2022 Dec; 102(12):1335-1345. PubMed ID: 36038734
[TBL] [Abstract][Full Text] [Related]
7. DACH1 suppresses epithelial to mesenchymal transition (EMT) through Notch1 pathway and reverses progestin resistance in endometrial carcinoma.
Zhou Q; Li W; Kong D; Liu Z; Shi Z; Ma X; Li Y; Jiang J
Cancer Med; 2019 Aug; 8(9):4380-4388. PubMed ID: 31215145
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway.
Wang Y; Wang Y; Zhang Z; Park JY; Guo D; Liao H; Yi X; Zheng Y; Zhang D; Chambers SK; Zheng W
Oncotarget; 2016 Mar; 7(9):10363-72. PubMed ID: 26824415
[TBL] [Abstract][Full Text] [Related]
9. Targeting cancer stem cell signature gene SMOC-2 Overcomes chemoresistance and inhibits cell proliferation of endometrial carcinoma.
Lu H; Ju DD; Yang GD; Zhu LY; Yang XM; Li J; Song WW; Wang JH; Zhang CC; Zhang ZG; Zhang R
EBioMedicine; 2019 Feb; 40():276-289. PubMed ID: 30594556
[TBL] [Abstract][Full Text] [Related]
10. Roles of SIRT1/FoxO1/SREBP-1 in the development of progestin resistance in endometrial cancer.
Wang Y; Zhang L; Che X; Li W; Liu Z; Jiang J
Arch Gynecol Obstet; 2018 Nov; 298(5):961-969. PubMed ID: 30206735
[TBL] [Abstract][Full Text] [Related]
11. Overexpressed epidermal growth factor receptor (EGFR)-induced progestin insensitivity in human endometrial carcinoma cells by the EGFR/mitogen-activated protein kinase signaling pathway.
Ai Z; Wang J; Wang Y; Lu L; Tong J; Teng Y
Cancer; 2010 Aug; 116(15):3603-13. PubMed ID: 20564127
[TBL] [Abstract][Full Text] [Related]
12. Dual-specificity phosphatase 6 plays a critical role in the maintenance of a cancer stem-like cell phenotype in human endometrial cancer.
Kato M; Onoyama I; Yoshida S; Cui L; Kawamura K; Kodama K; Hori E; Matsumura Y; Yagi H; Asanoma K; Yahata H; Itakura A; Takeda S; Kato K
Int J Cancer; 2020 Oct; 147(7):1987-1999. PubMed ID: 32159851
[TBL] [Abstract][Full Text] [Related]
13. Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma.
Bourguignon LY; Wong G; Earle C; Chen L
J Biol Chem; 2012 Sep; 287(39):32800-24. PubMed ID: 22847005
[TBL] [Abstract][Full Text] [Related]
14. Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway.
Corominas-Faja B; Cufí S; Oliveras-Ferraros C; Cuyàs E; López-Bonet E; Lupu R; Alarcón T; Vellon L; Iglesias JM; Leis O; Martín ÁG; Vazquez-Martin A; Menendez JA
Cell Cycle; 2013 Sep; 12(18):3109-24. PubMed ID: 23974095
[TBL] [Abstract][Full Text] [Related]
15. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells.
Song WS; Yang YP; Huang CS; Lu KH; Liu WH; Wu WW; Lee YY; Lo WL; Lee SD; Chen YW; Huang PI; Chen MT
J Chin Med Assoc; 2016 Oct; 79(10):538-45. PubMed ID: 27530866
[TBL] [Abstract][Full Text] [Related]
16. Molecular tools to reestablish progestin control of endometrial cancer cell proliferation.
Dai D; Kumar NS; Wolf DM; Leslie KK
Am J Obstet Gynecol; 2001 Apr; 184(5):790-7. PubMed ID: 11303185
[TBL] [Abstract][Full Text] [Related]
17. Bone Marrow-Derived Cells in Endometrial Cancer Pathogenesis: Insights from Breast Cancer.
Ferrer AI; Einstein E; Morelli SS
Cells; 2022 Feb; 11(4):. PubMed ID: 35203363
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor signaling pathway involved in progestin-resistance of human endometrial carcinoma: In a mouse model.
Xu Y; Tong J; Ai Z; Wang J; Teng Y
J Obstet Gynaecol Res; 2012 Dec; 38(12):1358-66. PubMed ID: 22612393
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer.
Gu C; Zhang Z; Yu Y; Liu Y; Zhao F; Yin L; Feng Y; Chen X
Cancer Sci; 2011 Mar; 102(3):557-64. PubMed ID: 21205080
[TBL] [Abstract][Full Text] [Related]
20. Prolonged progestin treatment induces the promoter of CDK inhibitor p21 Cip1,Waf1 through activation of p53 in human breast and endometrial tumor cells.
Kester HA; Sonneveld E; van der Saag PT; van der Burg B
Exp Cell Res; 2003 Apr; 284(2):264-73. PubMed ID: 12651158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
